medigraphic.com

2020, Number 1

<< Back Next >>

Rev Hematol Mex 2020; 21 (1)

Clinical-demographic characterization and prognostic exploration of patients diagnosed de novo with multiple myeloma seen in IPS Dynamics 2018

Cuervo-Pérez JF, Jaramillo-Arbelaez P, Lozano-Bohorquez DM, Bautista-López J

Language: Spanish
References: 47
Page: 9-31
PDF size: 384.10 Kb.


ABSTRACT

Background: Multiple myeloma is the second most frequent hematological neoplasm, and its signs and symptoms are related to the increase of clonal plasma cells and the production of immunoglobulins.
Objective: To characterize the clinical and demographic conditions of patients diagnosed with de novo multiple myeloma, in addition to make a prognostic approximation of them.
Material and Method: A descriptive and retrospective study of patients diagnosed with multiple myeloma, treated in IPS Dynamics during 2018.
Results: A total of 25 patients were included, most patients were men, with a median age of 62 years. The most affected laboratory parameters were the levels of hemoglobin and β-2 microglobulin. Morphological analyses of bone marrow showed that most of the spinal aspirates were hypercellular. The prognostic approach was made by grouping the results of the laboratory tests, especially flow cytometry, where it was evidenced that the expression of markers CD56, CD81, CD28 and CD117 were related to diverse clinical characteristics of relevance for the prognosis of the patient.
Conclusions: The characterization of the patients included in the study is very similar to that reported. The disease is more prevalent in men and the people most affected are those found in the seventh decade of life. The most affected laboratory parameters are hemoglobin and β-2 microglobulin concentrations.


REFERENCES

  1. O’Donnell E, Cottini NR F, Anderson. Williams Hematology. 9th ed. McGraw-Hill Education. New York USA, 2016;1733-72.

  2. San Miguel J. Multiple myeloma. Postgraduate Haematology. 6th ed. Wiley Blackwell, 2011;577-98.

  3. McKenna RW, Kyle RA, Khuel WM, et al. Plasma cell neoplasms. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer, Lyon France, 2017;241-53.

  4. GLOBOCAN 2018. World Health Organization (WHO). Fecha de consulta 01de noviembre de 2018 11:37 am. Disponible en URL: http://globocan.iarc.fr/Pages/burden_sel.aspx.

  5. Rajkumar SV, Dimopoulos MA, Palumbo A, et al.: International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48. doi: 10.1016/S1470-2045(14)70442-5.

  6. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Clin Trialsand Obs 2009;113(22):5418-22. doi: 10.1182/blood-2008-12-195008.

  7. Soderberg KC, Kaprio J, Verkasalo PK, et al: Overweight, obesity and risk of haematological malignancies: A cohort study of Swedish and Finnish twins. Eur J Cancer 2009;45:1232- 1238. https://doi.org/10.1016/j.ejca.2008.11.004.

  8. Davies FE, Avet-Loiseau H BP. Epidemiology, etiology and molecular pathogenesis. Remedica, London, 2010.

  9. Morgan GJ, Davies FE LM. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002;56:226-34. DOI: 10.1016/s0753-3322(02)00194-4.

  10. Blade J, Kyle RA, Griepp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996;93:345-351. DOI: 10.1046/j.1365-2141.1996.5191061.x.

  11. Solovev MV, et al. Epidemiology and clinical characteristics of patients with multiple myeloma. results of a prospective multicenter study in Russian Federation. Blood 2015; 126(23):4248. https://doi.org/10.1182/blood. V126.23.4248.4248.

  12. Segovia J, et al. Mieloma múltiple en el Hospital Universitario Fundación Santa Fe de Bogotá (1983-2006). Acta Méd Colomb 2008;33(4):276-281.

  13. Ferreira K, et al. Clinical characterization and survival of patients with multiple myeloma in a state of northeast Brazilian. Revista Cubana de Hematología, Inmunol y Hemoter 2017;33(2):1-9.

  14. Aguilar W. Aspectos epidemiológicos, clínicos y laboratoriales en pacientes con mieloma múltiple en el servicio de hematología del hospital materno infantil de la caja nacional de salud, periodo marzo 2012-febrero 2013. Rev Med La Paz 2016;22(2):36-41.

  15. Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011;204(1):3-12. doi: 10.1016/j.cancergencyto.2010.11.002.

  16. Wojciech Gorczyca. Plasma cell neoplasms. In: Atlas of Differential Diagnosis in Neoplastic Hematopathology. 3rd ed. 2014;359-81.

  17. Amor A. Discrasias de células plasmáticas. Gammapatías monoclonales. mieloma múltiple. Pregrado de Hematología. 4a ed. 2017;417-41.

  18. Oyaert M, et al. Use of multiparameter flow cytometry in multiple myeloma and other plasma cell neoplasms. Belg J Hematol 2015;6(2):46-53.

  19. Seili-Bekafigo I, et al. Myeloma cell morphology and morphometry in correlation with clinical stages and survival. Diagn Cytopathol 2013;41(11):947-954.

  20. Mateo G, San Miguel JF, Orfao A. Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 2005;113:5-24. DOI: 10.1385/1-59259-916-8:5.

  21. Kyle R, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33. DOI: 10.4065/78.1.21

  22. Nikhil C, Munshi, Sundar Jagannath. Plasma cell neoplasms. Hematology basic principles and practice. Philadelphia: Elsevier, 2013;1303-1337.

  23. McKenna RW, Kroft SH, Linden MA. Plasma cell neoplasms. Hematopathology 2nd ed. Philadelphia: Elsevier, 2015;473-496.

  24. Hernández M, García J, Raya Sánchez M, Moraleda Jiménez J. Anemia concepto, clínica y clasificación. Pregrado de hematología. 4ª ed. Madrid: Luzan 5, 2017;35-55.

  25. Dominiczak MH, Fraser WD. Metabolismo del hueso y homeostasis del calcio. Bioquímica Médica. 4a ed. 2014;343-352.

  26. Chesi M. Leif Bergsagel P. Pathogenesis of multiple myeloma. In: Multiple myeloma diagnosis and treatment. New York: Springer, 2014:35-46.

  27. Gazapo E, Gazapo R, Caturla A. Utilidad clínica de la determinación de β-2 microglobulina. Med Clin (Barc) 1996;106:751-755.

  28. Vivek R, Greipp P. Staging of multiple myeloma. Multiple myeloma diagnosis and treatment. Nueva York: Springer, 2014;47-53.

  29. Robert A, Rajkumar S. Criteria for diagnosis and response. multiple myeloma diagnosis and treatment. Rochester: Springer, 2014:1-15.

  30. Guo J, Su J, He Q, Li X, Zhao Y, Gu S, Fei C, Chang C, et al. The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma. Hematology. 2016 Apr;21(3):152- 61. doi: 10.1179/1607845415Y.0000000010.

  31. Lin P, Owens R, Tricot G, Wilson C. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482-488. DOI: 10.1309/74R4- TB90-BUWH-27JX.

  32. Bataille R, Jégo G, Robillard N, Barrille-Nion S, Harousseau J, Moreau P, Amiot M, Pellat-DC. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica 2006;91(9):1234-40.

  33. Gorczyca W. Plasma cell neoplasms. atlas of differential diagnosis in neoplastic hematopathology. 3rd ed. Boca Raton: CRC Press, 2014;359-381.

  34. Raja K, Kovorova L, Hajek R. Review of phenotypic markers used in flow cytometry analysis of MGUS and MM, and applicability of flow cytometry in other plasma cells disorders. Br J Haematol 2010;149:334-351. doi: 10.1111/j.1365- 2141.2010.08121.x.

  35. Reyes N, et al. Citometría de flujo en el estudio de discrasias de células plasmáticas. Rev Hematol Mex 2011;12(2):90-98.

  36. Paiva B. et al. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 2012;26:1862- 1869. doi: 10.1038/leu.2012.42. Epub 2012 Feb 15.

  37. Arana P, et al. Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia 2018 Apr;32(4):971-978. doi: 10.1038/leu.2017.320.

  38. Ribourtout B, Zandecki M. Plasma cell morphology in multiple myeloma and related disorders. Morphologie 2015;99(325):38-62. doi: 10.1016/j.morpho. 2015.02.001.

  39. Gema M, et al. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008;26: 2737-2744. doi: 10.1200/JCO.2007.15.4120.

  40. Schmidt-Hiebe M. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica 2011;96(2):328-332. doi: 10.3324/haematol.2010.031872.

  41. Sahara N, Takeshita A. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens. Leuk Lymphoma 2004;45:61-65. DOI: 10.1080/1042819031000149377.

  42. Kraj M,et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma 2008;49:298-305. doi: 10.1080/10428190701760532.

  43. Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma 2006;47: 43-47. DOI: 10.1080/10428190500272549.

  44. Harrington AM, Hari P, Kroft SH. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. Am J Clin Pathol 2009;132:60-66. doi: 10.1309/ AJCPOP7TQ3VHHKPC.

  45. Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, Ihara M, Ono T, Tamashima S, Nara K, Ohnishi K, Ohno R. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002;117:882-885. DOI: 10.1046/j.1365- 2141.2002.03513.x.

  46. Chen J, Neng Hsu S, Chuan Huang T, Ying Wu Y, Lin C, Ying Chang P, Chin Chen Y, Liang Ho C. Prognostic significance of initial serum albumin and 24 hour daily protein excretion before treatment in multiple myeloma. PLoS One 2015 Jun 8;10(6):e0128905. DOI:10.1371/journal.pone.0128905.

  47. Diem H, Fateh-Moghadam A , Lamerz R. Prognostic factors in multiple myeloma: role of β2-microglobulin and thymidine kinase. Clin Invest 1993;71:918-923. https:// doi.org/10.1007/BF00185604.




2020     |     www.medigraphic.com